Status:
RECRUITING
68Ga-FAPI PET/CT in Malignant Tumors
Lead Sponsor:
Zhongnan Hospital
Conditions:
Fibroblast Activation Protein Inhibitor
PET/CT
Eligibility:
All Genders
18-88 years
Phase:
NA
Brief Summary
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epitheli...
Detailed Description
The morbidity and mortality of malignant tumors are increasing. It is one of the major diseases that affect human health. At present, the conventional imaging diagnosis methods of a variety of maligna...
Eligibility Criteria
Inclusion Criteria:
Volunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor
Exclusion Criteria:
Female patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05034146
Start Date
February 23 2021
End Date
December 31 2025
Last Update
June 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071